Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 379 results for "Ibrutinib"

Pharmacyclics' Imbruvica gets European approval to treat two blood cancers
Pharmaceutical Business Review

Imbruvica receives European approval for two forms of blood ca...

Janssen-Cilag International announced that the European Commission has approved Imbruvica (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton's tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by ... PharmaBiz, 3 days ago
[x]  

3 images for "Ibrutinib"

OncLive, 22 hours ago
OncLive, 1 week ago
British Journal of Haematology, 2 weeks ago

IMBRUVICA (ibrutinib) ya está aprobado en Europa para el tratamiento de dos cánceres sanguíneos

SCHAFFHAUSEN, Suiza, 20 de octubre de 2014 /PRNewswire/ --Pharmacyclics Switzerland GmbH, una filial de Pharmacyclics, Inc. (NASDAQ: PCYC ), ha anunciado hoy que la Comisión Europea (CE) ha concedido una autorización de marketing para IMBRUVICA ...
 PR Newswire3 days ago La Comisión Europea aprueba IMBRUVICA para dos cánceres sanguíneos  PR Newswire6 days ago

Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration

Collaboration to evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in
 Technology Networks1 week ago Bristol Myers Squibb : Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® nivolumab and IMBRUVICA®ibrutinib in Non-Hodgkin...  4 Traders1 day ago
[x]  

Genetic mutation linked to acquired ibrutinib resistance in MCL

A relapse-specific BTK genetic mutation identified in patients with mantle cell lymphoma may serve as a target to overcome both primary and acquired ibrutinib resistance, according to results of a longitudinal study. Prior studies have found ...
 Orthopedics Today2 months ago
Pettinga Financial Advisors

Quest Diagnostics' (DGX) CEO Stephen Rusckowski on Q3 2014 Results - Earnings Call Transcript

Oct. 23, 2014 6:45 PM ET | About: Quest Diagnostics Incorporated (DGX) by: Quest Diagnostics Inc. (NYSE:DGX) Q3 2014 Results Earnings Conference Call Executives Dan Haemmerle - Executive Director, Investor Relations Stephen Rusckowski - ...
 Seeking Alpha11 hours ago Quest Diagnostics Q3 Profit Down, Updates 2014 Outlook - Quick Facts  RTTNews.com22 hours ago Quest Diagnostics Reports Third Quarter 2014 Financial Results  Pettinga Financial Advisors22 hours ago
[x]  

Quest Diagnostics Results Top Estimate; Sees FY Revenue At Top End Of Range

Quest Diagnostics Inc (DGX: Quote) said Thursday its third-quarter profit dropped from last year, when it recorded a massive one-time gain. Meanwhile revenues rose over six percent, on growth in diagnostic information services and some contributions ...
 RTTNews.com15 hours ago
Securities Technology Monitor

NeoGenomics is First to Offer Molecular Testing for Resistance to Bruton Tyrosin Kinase Inhibitors for Chronic Lymphocytic Leukemia

FT. MYERS, Fla., Oct. 23, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO) , a leading provider of cancer-focused genetic testing services, announced today that it has launched new tests for the detection of mutations in the Bruton tyrosine ...
 4 Traders22 hours ago
[x]  
Securities Technology Monitor

New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Sali

/PRNewswire/ -- Today, Analysts Review released its research reports regarding UnitedHealth Group Inc. ( NYSE: UNH ), Celgene Corporation ( NASDAQ: CELG ), Actavis plc ( NYSE: ACT ), Bristol-Myers Squibb Company ( NYSE: BMY ) and Salix ...
 A.M. Best1 day ago
[x]  

Johnson & Johnson : Reports 2014 Third-Quarter Results:

By a News Reporter-Staff News Editor at Diabetes Week -- Johnson & Johnson (NYSE: JNJ) announced sales of $18.5 billion for the third quarter of 2014, an increase of 5.1% as compared to the third quarter of 2013. Operational results increased 5.8% ...
 4 Traders1 day ago RESEARCHERS AT PFIZER REPORT NEW DATA ON MEDICINAL CHEMISTRY (BRUTON'S TK INHIBITORS : structural insights and evolution of clinical candidates)  4 Traders2 months ago
Pharmafocus

Pharmacyclics Signs Agreement with Roche

Pharmacyclics reported that it has entered into a master clinical drug supply agreement with Roche to evaluate the safety, tolerability and preliminary efficacy of Imbruvica (ibrutinib), in combination with Gayza (obinutuzumab) in patients with ...
 Individual.com3 days ago Pharmacyclics, Roche Enter Clinical Drug Supply Pact  Contract Pharma3 days ago Roche and Pharmacyclics agree leukaemia pact  Pharmafocus6 days ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less